An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy

Supportive Care in Cancer

Volumn 23, Issue 1, 2015, Pages 55-59

  Hegerova, Livia T ^a   Leal, Alexis D ^a   Grendahl, Darryl C ^a   Seisler, Drew K ^a   Sorgatz, Kristine M ^a   Anderson, Kari J ^a   Hilger, Crystal R ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Fosaprepitant; Highly emetogenic chemotherapy; Neurokinin 1 receptor antagonist; Phlebitis

Indexed keywords

ANTHRACYCLINE; APREPITANT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSAPREPITANT; GEMCITABINE; NAVELBINE; PLATINUM; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DEMOGRAPHY; DRUG EXTRAVASATION; DRUG INDUCED DISEASE; FEMALE; HUMAN; INJECTION SITE SWELLING; MALE; PHLEBITIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; VENOUS TOXICITY; CHEMICALLY INDUCED; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NAUSEA; NEOPLASMS; VOMITING; YOUNG ADULT;

ADULT; AGED; ANTHRACYCLINES; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; PHLEBITIS; RETROSPECTIVE STUDIES; VOMITING; YOUNG ADULT;

EID: 84919338437     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2326-9     Document Type: Article

References (17)

1. Celio L, Ricchini F, De Braud F (2013) Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence 7:391–400
2. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494
3. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198
4. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–243
5. National Comprehensive Cancer Network: clinical practice guidelines in oncology: antiemesis, version 1. 2013. 2013. http://www.nccn.org/professional/physician_gls/PDF/antiemesis.pdf. Accessed June 24th, 2013.
6. Van Belle SJ, Cocquyt V (2008) Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opin Pharmacother 9(18):3261–3270
7. dos Santos LV, Souza FH, Brunetto AT, Sasse AD (2012) da Silveira Nogueira lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 104(17):1280–1292
8. Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431
9. Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080–2087
10. Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29(11):1495–1501
11. Langford P, Chrisp P (2010) Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid 5:77–90
12. Leal A, Kadakia K et al (2013) Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer, Accepted August
13. Fujii T, Nishimura N, et al. Impact of fosaprepitant use on dermal and vascular adverse events in anthracycline-based regimens administered through peripheral lines. J Clin Oncol. 2013;31 (suppl; 9629).
14. Lasseter KC, Gambale J, Jin B et al (2007) Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47(7):834–840
15. EMEND (fosaprepitant dimeglumine) for injection [package insert]. In. Whitehouse Station, NJ: Merck & Co., Inc.
16. Saito H, Yoshizawa H, Yoshimori K et al (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24(4):1067–1073
17. Rogers MP, Blackburn L (2010) Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Clin J Oncol Nurs 14(4):500–504